Gilead's HIV Prevention Breakthrough and Global Health Efforts
Money

Gilead's HIV Prevention Breakthrough and Global Health Efforts

authorBy Bola Sokunbi
DateJun 22, 2026
Read Time2 min

Gilead Sciences, Inc. is making significant strides in public health, particularly in HIV prevention and infectious disease management. With a relatively low short percentage of shares outstanding at 2.07%, Gilead is recognized among top longevity and anti-aging investment options, highlighting investor confidence in its long-term potential. Its innovative research and development pipeline continues to yield promising results, reinforcing its position as a leader in the biopharmaceutical sector.

A major regulatory milestone was achieved on June 15, when the U.S. Food and Drug Administration (FDA) accepted Gilead's supplemental New Drug Application for Yeztugo 300-mg tablets. This potential once-weekly oral pre-exposure prophylaxis (PrEP) treatment for HIV prevention has a Prescription Drug User Fee Act (PDUFA) target action date of February 2, 2027. If approved, Yeztugo could revolutionize HIV prevention by offering a more convenient dosing option, thus expanding Gilead's comprehensive HIV prevention offerings.

Beyond HIV, Gilead is actively engaged in global health initiatives. On June 12, the company announced the donation of over 2,000 vials of its intravenous antiviral therapy, remdesivir, to Uganda. This donation aims to support the country's efforts in combating the ongoing Ebola Bundibugyo virus outbreak. This act underscores Gilead's rapid response capabilities to health emergencies worldwide and its dedication to leveraging its extensive expertise in infectious disease management to assist affected communities.

Headquartered in Foster City, California, and founded in 1987, Gilead Sciences, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing transformative therapies for life-threatening conditions. By focusing on virology, oncology, and inflammation, Gilead aims to convert severe illnesses like HIV and Hepatitis C into manageable, long-term health states. The company's continuous innovation and philanthropic endeavors demonstrate a strong commitment to improving global health outcomes and fostering a healthier future for all.

More Articles
Money
Novo Nordisk: A Leading Player in Longevity and Anti-Aging Market
Novo Nordisk A/S, a prominent global healthcare firm, is recognized as a top longevity and anti-aging stock. With a short interest of 0.51%, the company received an upgraded price target and a 'Buy' rating from Berenberg analyst Kerry Holford on June 17. The UK's Medicines and Healthcare products Regulatory Agency recently approved their oral GLP-1 therapy, Wegovy, for weight management, expanding their obesity treatment options with a non-injectable alternative.
By Scott PapeJun 22, 2026
Money
AON: A Leading Pet Care Stock for Sustainable Recurring Revenue
Aon plc (NYSE: AON) is recognized as a top pet care stock for consistent recurring revenue, despite recent price target adjustments from UBS and Piper Sandler. The company, a professional services firm, offers risk management, insurance, and human capital consulting, and collaborates with insurance providers to deliver customizable pet insurance solutions. Its resilient business model and diverse offerings position it strongly within the industry, although some analysts suggest exploring AI stocks for potentially higher upside.
By Natalie PaceJun 22, 2026
Money
AMD Bolsters AI Capabilities with Rackspace Partnership and MEXT Acquisition
Advanced Micro Devices (AMD) is expanding its artificial intelligence infrastructure through a significant partnership with Rackspace Technology. This collaboration will deploy AMD-powered computing infrastructure across Rackspace's global data centers, enhancing AI capabilities. Additionally, AMD's acquisition of MEXT, an AI-driven memory optimization company, further strengthens its position in addressing memory constraints in modern data centers and supporting advanced AI applications.
By JL CollinsJun 22, 2026
Money
TechnipFMC plc (FTI) Surges Amidst Bullish Market Dynamics
TechnipFMC plc (FTI) experienced significant gains in the first quarter of 2026, as detailed in Polen Capital's latest investor letter. The company, a global leader in offshore oil and gas equipment and services, saw its shares rise by 85.41% over 52 weeks, driven by robust order intake, expanding backlog, and improved project execution. This rally occurred despite broader market volatility influenced by AI disruption, private credit concerns, and geopolitical tensions.
By Mr. Money MustacheJun 22, 2026
Money
Pax8 CEO Scott Chasin Highlights Shifting IT Spending Landscape Towards SMBs
During a fireside chat at Pax8 Beyond 2026, Pax8 CEO Scott Chasin discussed the significant shift in IT spending, noting that the total addressable market (TAM) for small and medium businesses (SMBs) has surpassed that of large enterprises. This change is largely attributed to the rise of AI-native businesses. Chasin also emphasized the vast, untapped potential for deploying agentic AI within SMBs, highlighting that only a small fraction of managed service providers currently serve the global SMB market.
By Natalie PaceJun 22, 2026